Invention Grant
- Patent Title: Dosing regimen for a selective S1P1 receptor agonist
-
Application No.: US15534929Application Date: 2015-12-10
-
Publication No.: US10220023B2Publication Date: 2019-03-05
- Inventor: Jasper Dingemanse , Matthias Hoch , Andreas Krause
- Applicant: ACTELION PHARMACEUTICALS LTD
- Applicant Address: CH Allschwil
- Assignee: ACTELION PHARMACEUTICALS LTD
- Current Assignee: ACTELION PHARMACEUTICALS LTD
- Current Assignee Address: CH Allschwil
- Agency: Hoxie & Associates LLC
- Priority: WOPCT/EP2014/077469 20141211; WOPCT/EP2015/058202 20150415
- International Application: PCT/EP2015/079208 WO 20151210
- International Announcement: WO2016/091996 WO 20160616
- Main IPC: A61K31/426
- IPC: A61K31/426 ; A61K9/00
Abstract:
The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
Public/Granted literature
- US20180147188A9 DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST Public/Granted day:2018-05-31
Information query
IPC分类:
